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Introduction
Although familial clustenng of venous thiomboembohc events was
observed at the statt of this Century, it was not until the late nmeteen-
seventies before our insight mto the orgamzation of the haemostatic and
fibnnolytic Systems was sufficiently complete to enable a Start to be
made on a systematic seatch for genetic defects associated with
familial thrombosis The discovery that hetei ozygosity of antithrombm
deficiency co-segregdted with the thiombotic tendency m affected
families seemed to make a strong case foi the association between
single gene detects and thrombosis The results of these systematic
studies had been m part very fuutful and could be considered in the
context of two prmciple endogenous anticoagulant pathways (Fig 1).
the antithiombin-heparan sulphate pathway and the protem C/protem S
(PC/PS) pathway However only three single gene disorders had been
identified that were associated with a significant increase in the nsk for
venous thrombembohsm m tamihes identified through a symptomatic
deficient patient. with one of antithrombm, PC or PS deficiency
The awaieness that m 85% of tamihes piedisposed to thiombosis
no explanation could be found foi the clustenng of this disorder
sümulated the search for alternative approaches A major bieakthrough
m the study of familial thrombosis has been achieved dunng the past
two years Fustly, the concept and investigation of activated protem C
tesistance (APC-R) was mtioduced and, secondly, a mutation in the
factoi V gene (1691 G -» A m exon 10, leadmg to 506Aig to Gin)
was identified äs the moleculai basis tor the phenotype of APC-R in
the large majonty of aftected individuals (2,3) This mutation, which is
associated with a significant increase m thtombotic nsk (3-5), has been
tound in about 50% of selected tamihes with thrombophiha and in 20%
of consecutive patients with thiombosis A consequence ot this advance
has been a conceptual change in how thiombophiha is viewed, which
has imphcations tor diagnosis and tieatment of the disoider This
leview [published m two parts, see also (6)] attempts to summanse
lecent progress and to present lecommendations toi diagnosis, treat-
ment and reseatch m developed and developmg countnes
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Pathogenesis of Thrombophilia and Definition
of Inherited Thrombophilia
Thrombophilia is a tendency to thrombosis The predisposmg
defects do not necessanly cause contmuous climcal impairment they
need only weaken the abihty to cope with fluctuations mduced by
mteractions with the envuonment Clmicians usually apply the term
thrombophiha only to a subset ot patients with atypical thrombosis
Fiequently cited features mclude (1) eaily age of onset (2) hequent
recurrence. (3) stiong family history (4) unusual. migraton 01
widespread locations, and (5) seventy out of propoition to any
lecogmzed Stimulus Theie aie patients (see below) with fulminant
thiombophiha who, without theiapy. thiombose contmuoush But m
most patients thiombosis is episodic, separated by often piolonged
asymptomaüc penods The discontmuity suggests that theie is some
tnggei foi each event, peihaps a duect Stimulus a tempoiary detenora
tion of intnnsic tesistance, 01 some combmation of these tactors
The term mhented thiombophiha acknowledges the piesence of an
mhented factoi that by itself predisposes towaids thrombosis but due
to the episodic nature of thiombosis, requnes mteraction with othei
components (mhented or acquned) bei01 e onset of the climcal disorder.
see Fig 2 Undoubtedly the concept of mhented thiombophiha is an
opeiational one, the dehmtion of which has undeigone contmuous
lermement It was ongmally based upon early piesentation of thiombo-
sis. usually coupled with mhented phenotypic abnormality ot one öl the
mhibitory piotems, antithiombm, PC or PS Progress m the molecular
basis of thrombosis has enabled a moie genetically based dehmtion
to be foimulated Inherited thiombophiha h a genettcalh deteinnned
tendenc\ to venous thiomboemboliiin Dominant abnoimahnes 01
combmatwns of leis were defects ma^ be chmcalh appaient fwm
eaih age of onset fieqiient lecunence 01 famih Inston Mildei tiatts
mav be ditcovered only b} laboiaton imeitigatwn All genetic
mfluences and theu mteraction aie not \et undei itood
The identified and potential genetic factoi s predisposmg toi thiom-
bophiha discussed fully below aie summansed m Table l In its
tootnote aie hsted some ot the many potential mteiacting acquned nsk
tactois
Molecular Genetic Basis of Inherited Thrombophilia
In what tollows theie will be a summai v ot the a\ailable in lo imat ion
on the natuie and heteiogeneity ot the moieculat detects associated
with the estabhshed genetic nsk tactois toi venous thiombosis anti-
thiombm deticiency, PC dehciencv PS dclicienc\ and factoi V gene
mutaiion In the subsequent paiagiaphs those genetic delects w i l l bc
(vil
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Fig l Representation of the two prmciple anticoagulant pathways known to
be important m the regulation of Coagulation protemase activity To the left of
each diagram is a simplified view of the Coagulation cascade illustratmg the
positive 'procoagulant' feedback loops by which thrombin activates factors V
and VIII To the nght are the 'anttcoagulant" pathways bv which excessive
activation of Coagulation is prevented These pathways imolve antithrombm
(which directly mhibits the coaguiaüon piotemases such äs factor Xa
and thrombin), and PC/PS (which mactivate factor Va and factor Villa) PS
normally forms a complex with C4bBP and it is only the free form of PS that
acts äs a cofactor for PC
Risk Factors
Genetic + Genetic
Risk Factors
Genetic + Acquired
Venous thromboembolism
Λ? 2 Venous thrombosis can be caused by interactmg genetic and acquired
nsk factors
commonly referred to äs the P l-P Γ bond) Inhibition of most of the
blood coaguiaüon protemases is relattvely slow, but can be accelerated
at least 1000-fold by the bmdmg of hepann (and heparm-hke com
pounds, such äs endothelial cell hepann sulphate) to antithrombm
The mteraction between hepann and hepann-bmding domams m anti-
thrombm results m a conformational change of the molecule which
facihtates its mteraction with the protemase Inacme antithrombm
senne protemases complexes are rapidly cleared from the circulation
More Information on the structure, biochemistry and mechamsm of
action of antithrombm can be found m a number of iccent reviews
(7-9)
Human antithrombm cDNA clones have been isolated and se
quenced (10 12) The gene codmg for antithrombm is locahzed on
chromosome l between Iq23 and Iq25 (13), it is 13 480 bp long and
containssevenexons(l,2 3A, 3B 4,5,6)(14) , itsnucleotidesequence
has been lecently completed (15) Several sequence \auations or poh-
morphisms have been descnbed withm the human gene [for reviews see
(7-9)], mcludmg a highly polymoiphic trmucleotide repeat sequence m
mtron 4 The latter, particularly, seems useful for haplotype anaiv sis m
the study of recurrent mutations or Imkage analysis (16)
Antithrombin deficiency is a heteiogenous disorder The subclassifi-
cation of antithrombm deticiency was ongmally based mamly on the
results of functional and Immunologie assays m plasma Later after
more Information had become available on the actual mutations m the
antithrombm gene, the nomenclature was modified (17, 18) Presentlv
we recogmze type I antithrombm deficiency (identified by a concordant
reviewed for which the available studies still do not permit definitive
Statements to be made on their association with a thiombotic nsk
Antithrombm Deficiency
Antithrombm is a smgle chain plasma glycoprotem (58 kDa) which
belongs to the superfamily of the Senne Protease Inhibitois (serpms) It
is synthesized in the hver and its concentration m plasma is 2 5 μΜ
Antithrombin is the pnmary mhibitor of thrombin and also mhibits
most of the other activated senne protemases m\olved m blood
Coagulation (factor Xa, factor fXa, factor XIa. factor Xlla, kalhkrein)
It is therefore one of the most important physiological regulators ot
fibnn tormation
Inactivation ot protemases by antithrombm occuis \ ui the tormation
of an irreversible l l molar complex, m which -\ig393 toi ms a
stabihsed bond with the active site of the protemase The stable bond
totms äs the protemase attempts to cleavc the mhibitoi Aig 393-Ser
394 bond (this bond is at the reactive centie ot ant i thiombm and is
Tobte l Possible causes of mherited thrombophilia
(I) Inhei ited
Antithrombm deficiency PC deiiciency PS deficiencv
APC R/factor V 506Arg Dysfibrmogenaemia Thrombomodulm
toGln
(u) Acquired/Inhented(precise relative contnbution äs \et uncertain)
Hyperhomocystememia Elevated factor VIII Elevated fibnnogen1
(in) Potentmllv Inhented (butfirm e\ideiue lackmq)
Plasmmogen deticiency Hepann cotactor II Elevated histidme
detiuencj rieh glycopiotem
Plasmmogen activator Elevated plasmmogen
deiiciency' activator mhibitoi '
As discussed m the text there is yet no hrm evidence that conditions listed im
dei (m) are hnked to mherited thrombophilia The development ot thiombosis
is thought otten to be uiused by mtei action between genelic and nquired
laüors the best iec.ogmsed öl the lattci bemg advanung age immobilisation
mapr surgery orthopaedic suigery and neurosuigery pregnancy puerpertum
use ot oestrogen-contammg hoimones malignancies and the antiphospholipid
syndiome
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reduction ot both functional and immunological antithrombm) and type
II antithrombm deficiency [also identihed b> a vanant antithrombm
molecule, which has a detect m the Reactive Site (II RS), a detect
atfecting the Hepaun Bmdmg Site (II HBS) or multiple tunctional
detects (Pleiotropic Etfect) (II PE)] From a clmical pomt ot view anti-
thiombm deticiency is heterogenous. see belovv with mutations caus-
mg type II HBS deficiency being ot much less nsk than those causmg
the other subtypes( 18. 19)
In 1991 the tust database ot antithrombm gene mutations was pub-
lished (20) A revision ot this database became available m 1993 äs a
leport of the Thrombm and its Inhibitors Subcommittee of the Scien-
titic and Standardization Committee ot the International Society on
Thrombosis and Haemostasis (SSC ISTH) (18) In the 1993 database
39 distmct mutations and nme whole or partial gene deletions (>30 bp)
are hsted (hat have been tound in type I antithrombm deficiency These
mutations will mtroduce a trameshift (plus prematwe termmation
codon), a dnect teimmation codon. a change in mRNA piocessmg or
unstable translation products In the type II deticiencies 11 diffeient
mutations have been repoited m the type II RS gioup, 1 1 m the type II
HBS group and 9 m the type II PE group Most of the mutations
found m type II RS patients concern the leactive site of antithrombm
(P12. ΡΙΟ, Ρ2, Pl and ΡΓ) Type II HBS mutations are located mamly
on the A, C and D α hehces, Sites that have been proposed to be
mvolved m hepaim bmding (21) Mutations pioducing pleiotiopic
effects (type II PE) mterestmgly all are located in stiand IC dose to
the C-teimmal end ot the piotein, this legion has been shown to be
essential both toi the stability of the protem and tor the tiansmission of
conformational changes that endow the protem with its antithiombm
activity (both m the piesence and absence of hepaim) (22) Smce the
publication of the fust levision of the mutation database several leports
on novel mutations in the antithrombm gene have been published
(23-27)
Recunent mutations are tound in all types of antithiombm deticien-
cy, but especially m the type II HBS From the 21 distmct repeat
mutations 9 mvolved a CpG dmucleotide (hotspot tor mutation) Only
prelimmary infoimation is available (16) that addresses the issue of
whethei these recurrent mutations are the result of mdependent
mutations or of a founder effect (identity by descent)
PC is a vitamm K dependent plasma glycoprotem which is the
piecmsor of the senne protemase Acüvated Protein C (APC) PC is
synthesized m the hver äs a smgle cham molecule (62 kDa) Smgle
cham PC is converted mto a two cham molecule by lemoval of a
dipeptide (Aigl57 - Thrl58) probably m the Golgi In plasma most ot
the PC is in the two cham form (41 kDa heavy cham and 21 kDa light
cham), the concentration ot PC m plasma is 65 nM and is reduced
dm mg tieatment with oial anticoagulants
PC is a multimodulai piotein the ammo termmal light cham
contams a 7-carboxyglutamic acid rieh domain (Gla-domam) and two
Epideimal Growth Factor hke domams (EGF domams) These domams
have been tound to be mvolved m the tormation ot Ca:+-mduced
contoimational changes, bmding to phosphohpid suitaces, the actna
tion of the molecule and its mteiaction with other piotems (such äs its
cotactoi PS), while the carboxyteimmal heavy cham contams the sei me
piotemasc moiety ot the molecule
Dm mg coagulation PC can bc activated by thiombm via cleavage ot
the Argl69-Lcul70 bond This reaction (which is noimally very slow)
can be gieatly accclciated by the bmding öl thrombin to thiombo-
modulm, a transmembiane piotein receptor present on the membrane of
endothelial cclls The APC. thus tormed, mactivates the cofactors,
tactor Va and Villa, by selectue proteolytic cleavages To do this
etficiently APC needs to torm a complex with PS on a suitable mem-
brane surface Apart from these anticoagulant properties. APC also has
antitibrmoKtic ptoperties and anti-mflammatoiy etfects More detailed
infoimation on structural. biochemical and tunctional aspects ot PC can
be tound in recent review aiticles (28-30)
Human cDNA clones have been isolated and sequenced (31. 32)
Also the structme of the gene (PROC) has been tesohed (33. 34) u
contams 9 exons and 8 mtions on 11 kb of genomic DNA The gene
transcnpt is 1795 bp It contams a 5' untianslated region of 74 bp a
protem codmg region (exons 2-9) and a 3' untranslated region ot
294 bp The gene has been mapped to the cmomosome 2ql3-ql4
region (35)
A numbei ot DNA sequence polymorphisms are known to occur m
the PC gene, both m the piomotor region and m the codmg region
(36, 37) None of these vanations leads to an ammo acid dimorphism
All these polymorphisms have been foimatted for detecüon by PCR
This is also tiue for the two restnction fragment length polymorphisms
(RFLPs), reported by te Lmtel-Hekkert et al that are located ~7 kb
5' to the PROC gene (38)
PC deficiency is a heteiogenous disorder (37, 39) A phenotypic
subclassification has been proposed that is based on the results of func-
tional and Immunologie PC assays In type I PC deficiency there is a
concordant reduction m PC activity and PC antigen, while m type II PC
deficiency there is eudence tor the piesence of an abnormal PC mole
cule (leduced PC actn ity normal PC antigen) A furthei classification
of the type II PC deficiency can be made by compaimg the results of
diffeient functional tests (clottmg lest versus chromogenic test)
In May 1995, the first Update of the data base of PROC gene
mutations was published on behalt of the Subcommittee on Plasma
Coagulation Inhibitois ot the SSC ISTH (37) The database iontams
331 entnes denved fiom 315 umelated probands In total 160 different
mutations were reported that had resulted in type I or type II PC
deficiency Suipusingly -60% (n = 132) of the mutations (n = 28)
causmg type I PC deticiency are missense mutations Probably these
ammo acid substitutions lead to changes in the mteractions with other
lesidues and thus mteifeie with protem foldmg, a condition associated
with rapid mtracellulai degradation of the protem Missense mutations
leadmg to type II PC deticiency predommantly are located m surface
and solvent accessible aieas ot the protem that are lelevant tor the
function of the protem (hke propeptide cleavage, calcium bmding, acti-
vation, mteraction with thrombomodulm. active site. Substrate bmding)
(40,41) Further, theie are mutations m the promoter and 5' untranslat-
ed tegion, sphce site abnormahties. small deletions and msertions
(eventually leadmg to a prematme termmation codon) and nonsense
mutations that also aie responsible for type I deticiency
About 30% of the umque events occur m CpG dmucleotides and are
C ->· T and G -»· A transitions Interestmgly, 18 tiansitions m 16 differ-
ent CpG dmucleotides foim about 40% of all the entnes m the
1995 database At present theie is msutficient Information to
distmguish recuirent e\ents tiom events that aie identical by descent
PROC gene mutations have been lepoitcd now tor 18 true rtomo-
/ygotes (9 ot these had seveie clmical Symptoms) and 17 compound
heterozygotes (8 with seveie clmical Symptoms) PROC gene mutation
analysis has not howe\ ei solvcd an impoitant clmical and epidemiolog
ical issue that ot clmically lecessive and dominant loims ot PC
deticiency (see belo\\) The 1995 database aheady lists 14 dilferent
mutations that have been lound m both these tvpes ot PC deliciencv
Τίώΐί'2 PROS gene sequence \anations in patients with phenoUpii. PS
dehcienc\
Exon Codon. sequ mutat Predicted mutation Ref
1 - 2 5 , Ins T -25, Leu -» Leu (64)
f r a m e s h i f t , stop
2 - 2, G->T -2, Arg -> Leu (68)
2 - 1, G->A -1, Arg -> His (68)
2 22, C->A 22, Cys -» stop (68)
2 26, A-»C 26, Glu -4 Ala (68)
2 31, T-*G 3 1 , P h e - > C y s (68)
2 37, C^T 37, Thr -> Met (68)
3 43, de! A 43, Lys -> Asn (144)
f rameshi f t , stop
4 49, G->A 49, Arg -> His (68)
5 82, del T 82, Pro -» Pro, (145)
' f r a m e s h i f t stop
5 103, C->A 103, Thr -> Asn (68)
6 155, A-»G 155, Lys -4 Glu (69)
8 2 0 4 , A-»G 204, Asp -> Gly (68)
8 2 0 8 , G -»A 208, Glu -> Lys (68)
8 2 1 7 , A-»G 217, Asn -» Ser (146)
8 220, delG 220, Gly-» Glu (146)
f r a m e s h i f t , stop
8 2 2 4 , C^G 224, Cys -» Trp (68)
8 224, T-»C 224, Cys -4 Arg (68)
9 2 6 1 , delT 261, Leu -»Trp (65)
frameshi f t , stop
9 267, delG 267, Gly -» Gly (65)
f rameshi f t , stop
10 335, G^A 335, Asp -» Asn (68)
10 340, G-^T 340, Gly ^ Val (65)
12 4 4 8 , G^T 448, Gly -> stop (146)
13 467, T->G 467 Val -» Gly (65)
14 547-548, del AC f r a m e s h i f t , stop (146)
14 565, ms T 565, Val -> Val
f rameshi f t , stop
14 570, T-»C 570, Met -> Thr (146)
14 578, m s C 578 Pro -» Leu (65)
f r a m e s h i f t , stop
15 636, A - + T 636 stop -» Tyr (64)
new stop at 649
mtron d G -> A exon 4+1 (146)
mtron e G -» A exon 5+5 (68)
mtron j G -» A exon 10+1 (146)
mtron j G -» A exon 10+5 (64)
PS Defiticncy
PS is a vitamm K dependent plasma glycoprotem (70 kDa) It is
svnthesized m the hver, but also in endothehal cells. megakaryocytes
and Leydig cells m the testis The concentration ot PS m plasma is
25 μι/ml and is leduced durmg treatment with oral anticoagulants
PS is a multimodulai protem, it contams a •γ-caiboxyglutarmc ι ich
domam, a thrombin sensitive region, tour epidermal giowth tactor like
domains and a carboxytermmal legion which is highly homologous to
the sex hormone bmdmg globuhn (SHBG) PS seives äs a non-enzy-
matic cotactor ot activated protem C (APC) m the mactivation ot
tactois Va and Villa probably by tacilitatmg the loimation öl cnzyme-
substrate complexes on the surtace ot phosphohpid/platelet rhem-
branes This APC-cotactoi activity is destroyed by one ot three proteo-
lytic cleavages m the so-called "thrombin-sensitive region' (Aig49
ArgoO. Arg 70) In plasma PS circulates both tree (40%) and in a 1 1
stoichiometnc complex with C4b-bindmg protem (60%) The latter
compnses 7 identical α chams (70 kDa) and one single β cham
(45 kDa) which are hnked to each other m the carboxytermmal region
by disulphide bonds The β cham contams the PS bmdmg site Two
legions m PS have been repoited to be m\olved m bmdmg of the C4b
bmdmg protem (Gly605 to Ile614 and Gly420 to His434) Only the tree
form ot PS has APC cofactor activity More recently it has been
reported that PS itself also has anticoagulant activity under well-
detmed conditions it may tnhibit (m an APC-mdependent way) the
activity of both the tenase (IXa- Villa) and piothrombmase (Xa-Va)
complexes, some reactions bemg mdependent of the presence of
C4b-bmding protem (42-44)
A novel functional aspect of PS has been levealed recently tiom
studies teportmg on its bmdmg to the receptor tyrosme kmase known äs
Rse/Tyro 3 (45) and to a specific receptor on vascular smooth muscle
cells This might mdicate that PS also is mvolved in the regulation of
cell prohferation More detailed Information on structural. biochemical
and functional aspects of PS can be tound m a recent levtew aiücle
l A H\(47)
Human PS cDNAs have been isolated and sequenced (48-50) From
the cDNA nucleotide sequence the ammo acid sequence of human PS
has been denved Two highly homologous PS genes have been identi-
fied and sequenced (51-53) The PROS 01 PS« gene is the acttve gene
it consists of 15 exons which ate spiead over 80 kb of genomic DNA
and has been mapped to the chromosome 3 pl 1 1 -3 pl 1 2 legion (54)
The PSß gene shows 96 5% homology with PROS m exon sequences
and the positions ot the mtions are virtually identical to those m the
PROS gene However the PSß gene is a pseudogene. it contams onh
exons 2-15 and contams a laige vanety ot detnmental abenations
(a sphce site mutation, a hame shitt mutation and three stop codons)
With the use of a raie RFLP the pseudogene has been located withm
4 cM of the PROS gene (55) Several DNA sequence polymoiphisms
have been reported m the PROS gene (48 49,56) Some ofthese have
been very useful for tracking PS deticiency through famihes, foi
prenatal diagnosis and for evaluatmg the possibility of allelic exclusion
m the case of the study of reveise transcupts of platelet PROS mRNA
(57. 58)
Discussions on the subclassitication of PS deticiency have yet to be
fmalized Cuuently, two ot the three pioposed subclassification
Systems aie still m use, the System proposed by Comp m 1 990 (59) and
the pioposal recommended by the SSC ISTH in Munich, July 1992
Consistent with the subclassifications used for other hereditaiy deh-
ciencies, type I deficiencies/detects lesult m a reduction of total PS
antigen (and of free PS antigen and PS activity) Type II, 01 m Comp s
notation type üb, defmes the presence of a tunctionally abnoimal PS
molecule (total PS antigen noimai, fiee PS antigen noimal but PS
activity icduced) Type III PS deticiency (01 m Comp s notation type
Ha) is defmed by normal total PS antigen but leduced hee PS antigen
and activity Although this phcnotype seems to be lather pievalent, it is
not yet clcar whethei it is caused by a heieditary dcieü and if so
whethei it is hnked to the PS locus Recently Zoller et al lepoited that
both type I and type III phenotypes are leflections of the samc genotype
(60) Ftirthermoie, Duchemm et al lepoited among type III PS deti-
uencies an unusual high liequency (22%) öl a mutation pieviously
descnbed äs a raie polymoiphism (61) It concerns a T > C t iansi t ion
in codon 460 resulling m the icplacemcnt ot Ser460 by Ρίο in the
consensus sequence Ιοί the N-lmked glycosylation ot Asn458 (PS
Heeilen) (62) The l icquency ot the PS Heerlen allele in the general
Population is 05% and not ditteient trom that m thrombophihc
patients (0 79c) At present it is not clear \vhy this genotype is so
tiequent among t y p e III PS dehciencies
The genetiL a n a l y s i s oi the PROS genes ot symptomatic PS deticient
piobands has been hampeied and delayed bv the stmctuial complexity
ot the PROS gene and the existence ot the highly homologous pseudo-
gene \ t u i t h e i eomphcation is the unexpectedly lovv yield ot success-
l u l genetic analyses In thiee sepaiate studies mutations weie only
tound in 50 60% ot the patients. although all coding and flankmg
legions had been amphtied and sequenced (63-65)
Onl) two laige deletions m the PROS gene have been lepoited äs a
cause of a type I PS detiueney (66, 67) Agam. the majonty ot genetic
lesions causmg a type I deticiencv aie smgle nucleotide substitutions
msertions and deletions So tar 33 unique e\ents have been lepoited
see Table 2, but this number will mciease lapidly m the neai futuie At
piesent these numbeis aie too low to make any futther analysis Four
diffeient mutations have been repoited that cause a type II PS deficien-
cy (68,69), two m the propeptide, one m the fast EGF domam and one
m the second EGF domam Table 2 gives a summaiy of all the PROS
gene mutations lepoited to date m symptomatic PS deficient patients
In 1995, m Jeiusalem, the Subcommittee on Plasma Coagulation
Inhibitois of the SSC ISTH dectdcd to publish the first database ot
PROS gene mutations m 1996/1997
Faitoi V AI $506 to Gin
Factoi V is a smglc chain plasma glycoprotem (300.000 kDa) It is
synthesized m the hver and in megakaiyocytes Human plasma has a
concenttation ot 20 nM ot this piocofactot, while its concentiation m
platelets ts 4 μg/109 platelets Dunng blood coagulation factoi V is
convetted mto factoi Va by (meizo) thiombm and/οι tactoi Xa Throm-
bm-activated tactoi V is formed attei cleavages of the Aig709-Sei710,
Aigl01S-Thil019 and Aigl545-Serl546 bonds It is composed of an
amino teimmal tiagment (heavy chain 105 kDa) and a caiboxy termmal
tragment (light cham 74 kDa) non-covalently Imked via a tightly bound
Ca:+ lon Factoi Va seives äs a nonenzymatic cotactoi m piothrom-
bmase (factot Xa. phosphohpids, Ca2+) by mcreasmg the catalytic
efficiency approximately 2000-told Factoi Va light chain is lepoited
to contam the phosphohpid bmdmg site, while the heavy cham site is
mainly lesponsible toi the cofactot activity
Factoi Va is mactivated by pioteolytic degradation ot its heavy chain
by APC, this mactivation is moie etficient in the presence of phospho-
hpids and Ca2+ and is accoidmg to some an oideied and sequential
event with a tirst cleavage at Aig506 and subsequent mactivatmg
cleavages at Aig306 and Aig679 (70) Otheis demonstiated that two
tandom cleavages (mainly at Aig506 and Aig306) aie mvolved and that
both conüibute to the mactivation of tactoi Va (71)
Moie rccently it was lepoited that factoi V is not only a piocotactor
m the piothiombmase leaction but also a colactoi m the mactivation of
lactot Villa by APC (72) More mtoimation on the stiucture and tunc-
tion ot human tactoi V can be tound m a lecent leview (73)
Paitial and oveilappmg human tactoi V cDNAs have been isolatcd
hom HepG2 and human (letal) hvei cDNA libiancs (74-76) Fiom the
nucleotide sequence, the completc amino acid sequcnce ot factoi V was
denved It consists öl 2196 amino acids and shows a chaiactenstic do-
mam stiuctuic (Α,-Α-,-Β-Α,-^-Ο,) that is also lound m lactoi VIII
The chaiactenzation öl the human tactoi V gene was lepoited m 1992
h\ Cupe et al (77) Twenty l i ve cxons and 24 in t ions span appioxi-
matelv 80 kb genomic DNA The nucleotide sequence ot all coding and
flankmg regions has been deteimmed The factor V gene has been
mapped to chiomosome l ( lq21-25) and is closeh Imked to the anti-
thiombm gene (78) A number ot nucleotide sequence \anations m
human tactoi V cDNAs ha\e been identitied (74-76 79) but \vith some
exceptions (79 80) the allele trequencies ha\e not been reported The
microsatelhte maikei D1S61 has been mapped \ \ i th in 4 cVI ot the
tactor V gene locus and has been used successtulh toi trackmg the
tactor V gene m a tamil} with hereditary APC-R (})
In 1994 the smgle pomt mutation m the factor \ gene was identitied
äs the genetic detect causmg the phenotype ot APC-R m the \ äst majoi-
ity ot atfected mdividuals (3 5 81) It m\ol\es a G ->· A transition ot
nucleotide 1691 in exon 10. which piedicts the s\nthesis ot a \anant
tactoi V moiecule (factor V 506Aig to Gin 01 tactor V Leiden)
The mechamsm by which the mutation leads to the phenoupe ot
APC-R is still subject of detailed biochemical studies Hov,e\er it is
clear that the replacement of Aig506 by Gin will pie\ent clea\age ot
factoi V(a) at this site by APC and by that dela\ the mactnation ot
tactoi Va (82. 83) either by pieventmg the contoimaüonal change
necessary foi the mhibitoiy cleavage at Arg306 01 bv preventmg the
kmetically moie tavourable mhibitory cleavage at \ig506
So far the factoi V 506Aig to Gin mutation is the only genetic defect
identified in APC-R families It has a lelativeh high fiequenq m
Caucasian populations (up to -6%) but a much lower fiequenc\ m the
Japanese and othei Eastem populations (~09c) (84) Prehminan
evidence toi a foundei etfect in the spiead ot this disoidei was obtamed
trom the lesults ot haplotype analysis of 53 Dutch cameis ot the
mutation (3)
Other Canclidates'
Theie aie a numbei ot othei genetic detects 01 isolatcd deticiencies
that ha\e been imphcated m contitbuting to the iisk ot thiombosis m
tamihes with thiombophiha In most cases these ha\e been based on
obseivations m case-tamihes Sometimes genetic defects ha\e been
identitied but no data on genotype-phenotype relaüonships aie
available äs yet (85) In the next paiagraphs the vanous candidates will
be buefly discussed
Heiediian chsfibnnogenemm is detected by a piolonged plasma
thiombm time Clmical Symptoms vaiy hom none mild bleeding to
venous 01 aiteual thiombosis The phenotype ma\ follow iecessue 01
dominant inhentanie Recentlv the eudence toi a causal lelattonship
between an isolated dystibimogenemia and venous thrombosis has
been cntically leviewed and discussed bv a woiking paity ot the SSC
Subcommittee on Fibi mögen ot the ISTH (86) In that mvestigation
5 tamihes (tiom 5 diffeient countnes) weie identified m which apait of
the pioband. two 01 more tamily membeis had both the detect and
thiombosis In all tive cases the genetic detect had been identitied ( t w o
mutations m the Aa cham two mutations in the B β cham and one
mutation m the γ chain ot hbnnogen) In one tamih only homozvgotes
foi the mutation (tibrmogen Naples) weie chnicalh atfected The lela-
tionship between the dclect m the tibimögen moiecule and the
phenotype ot thiombophiha is s t i l l pooily undeistood Fuithei studies
aie hampeied bv the low tiequencv öl dvslibimogenemia m cohoits ot
palients with thiombosis (0 8%) (86)
Thioinlwmocliilin (TM) is anothei component öl the PC anti
uwgulant palhwa\ (47) It is a t iansmembiane protem synthesized b\
endothehal cells which acts äs a icceptoi loi thiombm and äs cotactoi
öl thiombm m the actnalion ot PC B\ analogy wi th PC and PS deti-
iienties one vvould expcct that deticiencies öl 01 detects m thiombo
moclulm may be associated wi th an mcreased nsk ot thiombosis
Unfortunately plasma is not an abundant source ot TM and theretore
cannot be used tor the laboratory diagnosis ot TM detects Analysis ot
the TM genes m cohorts ot symptomatic probands with a tamilv
history of thrombophiha did not reveal any alteration m the coding and
flankmg regions of the gene (0/30) in one studv (Reitsma PH & Berti-
na RM unpubhshed observations) while tour ditferent mutations
(4/87) vvere identitied by a second group (85 87) To date there is st i l l
very limited mtormation ot the co-segregation ot these mutations with
thrombophiha m the famihes of the piobands
Recently mild fape>hoino<.\stein<nnia was found in 19% of patients
with juvemle venous thrombosis and family studies showed that in
most cases this phenotype was mhented (88) Two large patient-control
studies have shown that hyperhomocystememia is a nsk factor for
lecurrent thiombosis (89) and for thiombosis m unselected patients,
among whorn elevated levels were present in 10% (90) Seveie hypei-
homocystememia has a population prevalence of ~1 300 000 and is
most frequently caused by homozygous c\statluomne β svnthase
deficiency Homocysteme is a sulphydryl amino acid denved üom
metabolic conversion of methiomne Its mtracellular metabohsm
occurs through remethylation to methiomne or transulphuration to
cysteine Cystathiomne ß-synthase is involved in the tiansulphmation
pathway A small number of cases of severe hyperhomocystememia are
caused by homozygous deficiency of methyleneteti ahydi ofolate reditc
tcife Gene defects m both of these metabolic enzymes are implicated m
mild hyperhomocystememia (91, 92) A recenth descubed mutation
with theimolabihty of methylenetetrafolate reductase may in the homo-
zygous state be a sigmficant and frequent cause for mild hypeihomo
cystememia (93)
Plasmmogen deficiency and d\5plasmmoqenemia have been repoit
ed frequently to be associated with thrombophiha Howevei, family
studies reveal that m most famihes with a type I plasmmogen deficien-
cy (parallel reduction of plasmmogen activity and antigen) only the
proband suffers from thrombotic disease (94) In a lecent retrospective
analysis of 20 famihes, heteiozygotes of a type I plasmmogen deficien-
cy weie found to expenence sigmficantly more thrombotic events
(although rather late m life) than their normal family members (95)
The frequency of plasmmogen deficiency m the general population
seems to be slighter lower (0 4%) to that m cohorts of patients with
thrombosis (l 3%) (96,97) Dysplasmmogenemia or type II plasmmo
gen deficiency (reduced plasmmogen activity, normal antigen) asso
ciated with Substitution of AlaoOl by threomne is a common vanant in
the Japanese population and seems not to be associated with thrombo
sis (98) Studies of plasmmogen deficiency at the DNA level are still
very tare
In a model in which it is expected that teduced plasmmogen levels
may cause thrombophilia it seems reasonable to propose that an mher-
ited elevated Hntidme Rieh Ghcopiotem (HRG) level m plasma is al-
so a nsk tactor tor thrombosis HRG (a non enzymatic protem) forms
a l l complex with plasmmogen m plasma (via bmding to its lysme
bmdmg sites) and thus leduces the free plasmmogen concentration to
aiound 50% (99) Complex tormation with HRG mteiferes with the
bmdmg ot plasmmogen to tibnn Although several tamihes with
thrombophiha and high HRG levels have been repoited (100 101)
theie is still no tormal evidente loi its association Surpnsmgly, recent-
ly two famihes have been leported where a partial deticiency öl HRG
seems to be associated with thrombophiha (102 103)
Anothcr potential nsk tactot ot thrombosis, deticiency of the /mif i
Fiictoi Ρί/f/nwn Inlubitoi (TFPl) has been mvestigated but no muta-
tion m TFPl genes öl 30 symptomaiic piobands of famihes with ihmm-
bophiha (Reitsma PH & Bertina unpublished obsenations) could be
found Other potential candidate nsk tactors tor thrombosis are hepa
nn Lofactoi II defiuenc\ and ß-, gl\u>piotem I deficienc\ Laboiatorv
analysis ot large groups ot patients with thiombophiha and ot controls
revealed however, that the hequency ot heterozygotes tor these
detects among patients and controls is very similar (0 6% and 6%
respectively) (104 105) Nevertheless a tew famihes ha\e been leport
ed in which an isolated heparm cofactoi II deticienc\ seems to segre-
gate with the thiombophiha (106 107) In two famihes with a type II
heparm II cotactor deficiency the lesion m the gene was identified
(lepiacement ot Arg 189 by His) (108) This mutation is thought to
etfect the dermatan sulphate bmding site and is analagous to ceitam
detects m type II HBS antithrombm deticiency that effect the heparm
bmdmg
A last genetic defect that has been discussed dunng the last years
with respect to its possible association with thrombophiha is a partial
factoi XII deficiency Original studies from Mannhalter et al suggested
a high fiequency of heterozygotes for factoi XII deticiency m cohorts
ot thrombophilic patients (109) Subsequent studies have not suppoited
these fmdmgs (110)
Fmally there is a phenotype that recently has been identified äs a nsk
factor for thrombosis m large patient-control studies elevated factoi
VIII levels (111) The hereditabihty of this phenotype and the eventual
underlymg molecular defects have not been reported so far
Epidemiology of Inhented Thrombophiha
Pie\alence ofHeieditan Thiombophiha
Venous thrombosis has an overall annual mcidence of <1 m 1000 It
is lare m the young, and becomes more frequent with advancing age
The true pievalence of hereditary thrombophiha is not yet known It
seems cleai that we do not know all genetic abnormahties causmg a
tendency to venous thrombosis, since even m patients fiom famihes
selected on the basis of a high numbei of unexplamed thromboses m
only about half an underlymg defect will be tound(112) This indicates
that the prevalence of hereditaiy thrombophiha m the general popula
tion will be higher, possibly up to two fold than estimates from large
prevalence studies on the known genetic defects A high prevalence of
hereditary thrombophiha will make this an important factor m the over-
all mcidence of thiombosis This mav also be assessed by takmg the
piesence of a positive family histoiy mto account Among unselected
consecutive patients with deep vein thrombosis a tamily histoiy was
reported by one out ot every four patients (113) Even though a positive
family history may occur by chance äs venous thiombosis is not a laie
disorder, these figures mdicate that genetic causes are prominent m the
etiology of venous thiombosis
The prevalence ot deficiencies of PC and antithrombm has been
mvestigated m a veiy laige study ot almost 10,000 blood donors
(l 14-117), Table 3 Repeated testmg ot the le\els of these protems
coupled with tamily studies and DNA analvsis led to estimates of l m
500 toi PC deficiency and l m 5000 toi type I antithrombm deficiency
This is m the same lange ot the fmdmgs öl a pievious study among over
5000 blood donois where l m 250 weie consideied PC deficient ( 1 1 8 )
Although some caution is needed m mteipietmg data based on studies
among blood donois who are a seil selected sample from the general
population these seem to be fair estimates Vitcptmg the approximate
prevalence ot PC deticiency to be l 350 the prevalence öl severe
(homozygous 01 compound heteiozygous) deticiency wil l be l 700 X
l 7()0 = 4 9 Χ 101 Ottspimg liom iclated paients w i l l ot couisc have
much highci nsk ot s e v c i c cleliucni\ The p ie\a lence ot se\erc anti-
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rablc 3 Pre\alence ot the major
thromboplulic clotting ibnormalitits
Hialth\ i
T a i t e t a l (n = 9669) (l 14 117)
M i l c t t c h e t a l (n = 5422) (l 18)
S\ensson and Dahlb ick (n = l 30) (
Rosendaal et al (n = 474) (4)
Ridkere ta l (n = 704) (l 20)
C()iiKcuti\( patienft uithfnst DVT
Heijbocre ta l (n = 277) (111)
Koster et al (n = 474) (123)
Rostndaal et al (n = 471) (4)
Tluomboplulic patients
Briet et ai (n = 1 13) (147)
Schaneretal (n= 1581(148)
B e n T a l e t a l ( n = 107) (149)
Tabernoetal (n = 204) (l 50)
Griffin et al (n = 25) (l 12)
119)
PC PS Anmhrombin APC R
detiuenc\ dehuencv defiuencs
02 rc+
04%
3%+
8%
9%
6%
1%
13%
6%
002%'
4%
3%
7%
05%
7rr
3%+
20%+
32%
+ DNA confirmed ' t) pe I Antithi ombm deticiency
thiombm deficiency is hkel} to be 100 1000 less than se\ete PC
deficiency There are no studies of sufficient size on PS deficiency
among healthy individuals on which a reliable estimate ot its
prevalence can be based
Fot APC-R, the groups that have been studied are not äs large äs
m the blood donoi studies Howevei smce the prevalence of this
abnormahty ts an oidei ot magnitude htghet than the other mhibitoi
deficiencies the estimates aie ab tehable The estimates toi Caucastans
tange hom 3 to 7 percent (4119 120), and foi several studies aie based
on genetic mvestigation (4, 120) Smce these estimates aie also based
on seit selected individuals \uthoul a history of caidiovascular disease
or venous thiombosis they are under mthei than o\ei-estimates The
prevalence at birth ot homozygous factor V 506Gln mutatton has been
estimated at ~ l 5000 (4)
Among consecutive patients with objectively confumed deep vem
thiombosis, deüciencies of PC PS and antithrombm combmed account
for -5% APC-R is present m 20 percent ot consecutive patients with
deep-vem thiombosis (4, 121)
Seveial studies have tocused on selected patients with venous
thiombosis and usually tound a highei pie\alence of deficiencies of
PC, PS and antithrombm than has been lepoited among unselected
consecutive patients Diffeient cnteiia were used in selectmg the
patients for these series some authors mcluded patients who expen-
enced a first thrombosis at a young age others studied individuals with
tecurrent thrombotic events or thiombotic events that occuned m the
absence of any of the classical nsk factots foi venous thrombosis, while
some mcluded mdiuduals with a positive tatnily histoiy Because ot
these heterogeneous inclusion critena the prevalences that have been
leported m these studies should not be compaied too closely The
pievalences that ha\e been lepoited among selected patient groups foi
deticiencies ot PC PS and antithrombm aie mostly between 5 and
10%, much higher than the pre\ alenccs lound in Ihc population studies,
and also somewhat highei than the tiequency among consecutive unse
lected patients These highei prevalences in patients with thiombosis
than m healthy mdniduals and in thrombophilic individuals äs com
pared to unselected patients also mdicate that these deticiencies indeed
lead to venous thiombosis and \enous thiombophiha APC R appcais
to account tor halt ot all cases öl heieclitarv thiombophiha and cleaily
emetges tiom Table 3 äs the most important cause of heieditarv throm-
bosis and peihaps ot venous thrombosis m general
Risk of Venous Tluombosis
The nsk of venous thrombosis toi mdmduals with clottmg factor
gene abnormahties has laigeh been mvestigated bv two appioaches
tirst by studies in tamily membeis of piobands with one of these
abnormahties and second b\ population-based studies (case contiol
studies) These diffeient appioaches do not necessanly vield the same
Information The foimei aie based on tamihes in which the hereditabil-
ity of the abnormahty has been shov n bv mcludmg only tamihes \\ ith
one 01 more individuals with the clottmg abnoimahty apart fiom the
proband who is both symptomatic tor thrombosis and has the clottmg
defect In the analysis typicallv the occurrence of thrombosis is
compaied between the famih members with and without the clottmg
factoi abnoimahty while the proband is excluded from the analvsis
Smce hereditabihty is a preiequistte in studies of this design thev aie
most fitting to dnectly answei questions concerning nsks ot genetic
disordeis In population based studies patients with thrombosis
aie compaied to healthv mdmduals with legaid to the pievalence ot
clottmg tactor abnoimahties These case control studies yield ielat i \e
nsk estimates which mdicate how much highei the nsk of thrombosis
is tor an mdividual with a pamculai nsk tactoi compared to an mdi
vidual without that factor Smce onh indiMduals aie mcluded and not
famihes, no direct Statements about hereditabilttv lesult from these
studies Furtheimoie case control studies can only yield estimates ot
ielati\e nsks not of absolute (hte time) nsks
When consecutive patients are mcluded m a population-based stud\
(with population-controls) the lesults associatmg a particular nsk
lactoi with thrombosis apph indiscnminateiv to all individuals v\ i th
that abnoimahty m the population The results iiom famih studies aie
based on lamilies that stood out and \vcre lecogmsed because ot a
conspicuous high frequenu ot thiombosis stnctly speakmg these
lesults only apply to tamihes detected m a smiilai wav In othci words
population-based studies yield an a\eiage nsk lor individuals with a
paiticulai abnoimahtv wheicas lamih studies are conductcd among
those with highct nsks Smce i t is l i kch and has now been shov\n to be
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true tor APC-R that many tamihes vvith thiombophilia displav more
than one genetic abnoimalitv one should exercise extreme caution m
apphmg results f iom familv studies to unselected mdividuals 01
results trom population-based studies to thrombophihc tamihes It an
mdividual is identified äs tairymg a thiombogenic abnormahtv by
means ot a study among the general population m all hkehhood he
onK cames that one abnoimalit) if he is tound äs pioband ot a tamih
\vith thrombophiha he might well caiT} two 01 moie and it he is an
unselected patient vvith thiombosis he mav well be one of both
Antitliiombin Dejicienc\
When the data tiora all the available family leports of antithrombm
deticiencv are combmed it appeais to confer a highei nsk ot thiombo
sis than deticiencies ot PC and PS Thiombosis is not uncommon
betoie age 16 and about halt of the patients from these lepoited
tamihes expeuenced a first thrombotic event before age 25 (122 123)
Antithrombm deticiency especially has a rauch highei nsk ot thrombo
sis in pregnancy than deficiencies of PC or PS (124) The tifty fold
diffeience m the prevalence among patients with a tirst event ot deep
venous thiombosis and the prevalence m a healthy population (113
114 125) also suggests a highei thrombotic nsk m antithrombm defi
ciencv than in PC deficiency, although such a difference could not
be substantiated m a population-based studv (125) There is some
debate uhethei the moie severe form ot thrombophiha caused by anti-
thiombm deficiency might also lesult m mcieased moitahty (126 127)
in some pedigrees fatal thromboses have been obseived (128) but m
histouc studies of Dutch pedigrees no excess moitaht) was evident
(24 129)
PC Deficienc\
Smce 1981(130) many tamilies with heieditaiv piotem C deficien
cy have been leported The nsk ot thrombosis appeais not to be diffei-
ent tor the ditfeient types of piotem C deiiciency (t\pe I low plasma
le\el and type II low activity) noi foi the laige numbei of rautations
identihed m PC deficiency (37) In family studies it has been shown
that tamih members who are PC dehcient have an increased nsk of
\enous thrombosis (about 8 10 fold) and that by age 40 about half ot
them will have expenenced at least one thrombotic event (131, 132) In
a population-based study (125), a lelative nsk estimate of 7 has been
repoited which (surpnsmgly in view of the comments made above) is
\e iy similar to the relative nsk denved fiom familv studies The preva
lences leported m unselected patients with fast thiombotic event (3%)
(113 125) and healthy mdividuals fiom the geneial population (02%)
(117) also suppoit a telative nsk of this size or slightlv highei
These data all apply for heterozygous PC deficiencv m which PC
activitv on aveiage is 50 peicent of noimal The laie homozygous
patients with no PC activity m plasma has a much highei nsk of
thiombosis and develop puipuia tulmmans shoitlv atter birth (see
below)
PS Deficicnc\
Smce 1984 (133 134) many tamihes have been lepoited with
venous thrombophiha and PS dchciencv It is not cleai whethei the
Ihice different subtypes that have been desuibed (tvpes I II and III)
conlcr similar nsks ot thiombosis It is \ e iy di thuil t to ainve at nsk
cstimates foi PS deliuency smce the pievalcnce in the geneial popula
tion is unknown theie aie no lepoits tiom lamih studies lormalh
assessing the relative nsk the moleculai basis m many cases remains
unclear and several tamihes with APC-R appeai to ha\e been misclas
sitied äs PS deficient (type II) (135) In one population based case con-
trol studv the pievalence ot mdividuals vvi th lepeatedl) lovv levels ot
PS did not diffei between cases and tontrols which does not support an
association ot PS deficiency and venous thrombosis (125) It is difficult
to leconcile this findmg with the reports trom seveial tamihes äs well
äs the highei pievalence of PS deficiencv in selected patients vvith
thiombophilia than m unselected patients with a tust event (Table 2)
Although the available evidence generallv leads to the conclusion that
PS deficiency mcreases the nsk of thrombosis this evidence is rauch
less solid than for PC deficiency Homozvgous PS deficiencv has been
lepoited and vvhile extremely rare appeais to be äs seveie äs homo
zygous PC deficiency (see below)
APC RJFactoi V506Aig to Gin
In a study in 34 tamihes with APC R the life time nsk of thiombo-
sis was clearly highei m family membeis with this phenotvpe than m
those who did not (119) At age 50, about 25 percent of mdividuals with
APC-R had expenenced at least one thiombotic event (119) This is
lower than the figures reported foi famihes with PC deficiencv (132) it
should be borne in mmd, however, that these famihes with APC R weie
not selected on the seventy of thrombophiha äs was the case m familv
studies of PC deficiency In a population based case contiol study
APC-R was found in 21 peicent of patients with a first episode ot deep
vem thiombosis and m üve percent of controls which led to an estimate
öl the lelative nsk associated with APC-R of 7 (121) This nsk estimate
is veiy similar foi that found for PC deficiencv
Because of its high allele frequencv homozygous cainers of the
factoi V Aig506 to Gin alleles are not uncommon The homozygous
abnoimahly appears much less seveie than homozygous PC deticiencv
smce seveial of the homozygous patients have remamed thiombosis
fiee well mto adult life (4 136) Still the nsk of thiombosis toi those
homozygous foi the mutation is higher than ior those heteiozvgous
(10-fold higher), estimated at 90 fold increased compared to mdividu
als without the mutation (4)
Combmed Abnormalities
Deticiencies of PC, PS and antithiombm aie lare while APC R is
very common Because they aie so lare these foimei deticiencies have
been studied mostly in referred and highly selected famihes In these
selected famihes eg with PC deficiency, high nsks ot thiombosis
have been obseived (PC deficiency is then said to be climcallv
dominant), much higher than in lelatives ot patients homozvgous toi
PC deficiency (PC deficiency is then said to be climcallv tecessne)
(118) This discrepancy in clinical expression cannot be explamed bv
different mutations underlymg PC deticiency (37) The most plausible
explanation for the diffeience m clinical expiession in PC deticiencv
anses tiom the view that more than one abnoimality mav be lequired
lo cause thrombosis, see Fig 2 In patients vvi th homozvgous PC
deticiency, two identical detects are piesent so that then heterozvgous
lelatives will ölten have just one detect which caines a smallei nsk
Individuais with hetciozygous PC deticiency tiom hmihes \ \ i t h
stnkmg thiombophilia among heterozygous taineis might be expecied
to have additional abnormalities contnbutmg lo the nsk It has been
shown that APC-R may be such a second nsk tactoi and this ^xplams
why in ramily studies among selected lamihcs vvith th iombophi l ia the
nsk öl thiombosis amons non delicicnt l a m i l v mcmbcis \\as hmht i
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than m the gcneral population (132) many ot them had APC R (137)
In this study i t was shown that the combination of PC deticienc\ and
APC-R contened a higher nsk than eath ot these abnormahties
separately Similar conclusions have been drawn tegarding the m
creased nsk ot thrombosis following mteraction ot tactor V 506 Arg to
Gin mutation with the othei mhibitordetiuencies PS and antithrombm
deticiencies (138 140) The Situation with combmed tactor V 506Aig
to Gin and ant i thiombm mutation is lurther comphtated b\ their dose
genetic p iox imitv In some tamilies co segiegation ot tvvo genetic
detects can occur lesultmg m high thrombotic usk to all arfeued mdi-
Mduals(139)
Atquired nsk factors aie important in the development ot thrombo-
sis Unfoitunately theie are tew reported studies that contam quan-
titative Information It has been shown that the nsk ot thrombosis is
turthei mcreased among women with PC deficiency who use oial
contiaceptives (141), and is gieatly incieased among APC-R women
w h o use oral contraceptives (142) The nsk is leported to van with the
t)pe of progestagen used (143)
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